80 was found to bind favorably to Bcl-2 and Bcl-xL in the docking simulation analysis, suggesting that it is a probable small molecule Bcl-2/Bcl-xL inhibitor and a potential lead for breast cancer chemotherapy with apoptotic and anti-metastatic properties. Here, BCL2 is linked to breast carcinoma.